BioSpace News Archive

PhoreMost and Sixth Element Capital Announce Creation and Investment in NeoPhore, an Immuno-Oncology Company

Sixth Element Capital LLP announces a £3 million investment in NeoPhore, a spin out from Cambridge, UK based PhoreMost Ltd

November 15, 2017

·

1 min read

Pharma Set for Prosperous 2018 as 44,500* Attend CPhI Worldwide

Held in Frankfurt the world’s largest pharma event saw attendees from 169 countries - 25% of which are CEO or board level.

November 15, 2017

·

3 min read

Drug Development

Significant Improvements Reported in Duchenne Muscular Dystrophy Patients Treated With Capricor’s Investigational Cell Therapy

These findings were reported today by Ronald G. Victor, M.D. at a Late-Breaking Science session of the American Heart Association Scientific Sessions 2017.

November 15, 2017

·

9 min read

Drug Development

ADC Therapeutics to Present New Clinical Data for ADCT-402 and ADCT-301 at the American Society of Hematology 2017 Annual Meeting

The presentations will highlight the clinical data from ADCT-402 and ADCT-301, the two most advanced programs in its portfolio of ADCs targeting haematological and solid tumours.

November 15, 2017

·

5 min read

Business

Outpost Medicine Appoints Scott Byrd as CEO and Raises $20M in Series A Financing Extension

Byrd will be succeeding David Socks, Interim CEO and Co-founder of Outpost.

November 15, 2017

·

4 min read

Business

China Pharma Reports Third Quarter 2017 Financial Results

Revenues were $3.2M and $3.1 million for the three months ended September 30, 2017 and 2016 respectively.

November 15, 2017

·

23 min read

Business

GeneNews Announces Q3-2017 Financial Results Provides Progress Update

GeneNews today announced operational and financial results for the three-month period ended September 30, 2017, and provided a progress update on its business.

November 15, 2017

·

5 min read

FDA

Astrazeneca Gets Another Boost With FDA Approval of Severe Asthma Drug

The drug, in combination with abemaciclib, showed 16.4 Months of progression-free survival.

November 15, 2017

·

12 min read

Business

Xenetic Biosciences Reports 2017 Third Quarter Financial Results and Provides Corporate Update

Net loss for the nine months ended September 30, 2017, was $8.0 million compared to a net loss of approximately $53.8 million for the same period in 2016.

November 15, 2017

·

10 min read

Deals

Invitae Completes Acquisition of CombiMatrix, Becoming a Leader in Family and Reproductive Health Genetic Information Services

In connection with the closing, Invitae issued approximately $21.2M in shares of its common stock to former CombiMatrix securityholders, or approximately 2.7 million shares.

November 15, 2017

·

8 min read